research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK /STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
Search
for
Sort by
Research
750-780 / 1000+ results research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Fludalanine: Nice Try But No Hallelujah
Fludalanine failed as an effective oral antibiotic despite efforts.
research LB1011 Cost and access changes with TNFa inhibitor biosimilars entering the market
Biosimilars lower costs but don't significantly improve access.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
research 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research JAK Inhibitors in the Treatment of Lichen Planopilaris
JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
research Targeting Endogenous Wnt Antagonists for Therapy Development in AGA: a Focus on DKKs and sFRPs
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Anti-Acne Agents Attenuate FGFR2 Signal Transduction in Acne
Anti-acne medications may work by reducing the activity of a protein involved in acne development.
research Discovery of Orally Available Prodrugs of Itaconate and Derivatives
New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
research The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
research The CAP1/Prss8 catalytic triad is not involved in PAR2 activation and protease nexin‐1 (PN‐1) inhibition
CAP1/Prss8 does not activate PAR2 or inhibit PN-1.
research Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
research LB1059 Neuromediators associated with neurogenic skin inflammation promote M2 differentiation of macrophages in human skin ex vivo
Certain substances can help skin cells become anti-inflammatory, aiding in tissue repair.
research Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
research TRAIL sensitization of PC3 prostate cancer cells by doxorubicin can be blocked by the anti-oxidant N-acetyl-cysteine or by the iron chelator deferoxamine
Antioxidants can block the cancer-fighting effects of doxorubicin.
research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
research Biopharmaceutical research on the choice of a non-steroidal anti-inflammatory agent in the development of combination gel for mastopathy therapy
Indometacin was chosen for a gel to help treat mastopathy and prevent breast cancer.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Charting the Bromodomain BRD4: Towards the Identification of Novel Inhibitors with Molecular Similarity and Receptor Mapping
Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.